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Inclusion and exclusion criteria
The age of the patients was between 16 and 60 years, but some centers extended the age limit to 70 years depending on the policy of the center. Patients with blast crisis of chronic myeloid leukemia or with leukemias supervening after other myeloproliferative diseases were excluded from this study. Other exclusion criteria were: inadequate renal and liver function with creatinine and bilirubin values greater than 1.5 times the upper limit of normal, severe heart failure requiring diuretics or with an ejection fraction of less than 50%, and severe concomitant neurological disease. Patients with other progressive malignant diseases were also excluded from this study, but secondary acute leukemias following cured Hodgkin's disease or other malignancies were allowed, as were secondary leukemias following exposure to alkylating agents or radiation for any other reason.
Laboratory investigations
Apart from the other standard investigations it was mandatory to perform cytogenetic analysis with banding techniques prior to the start of chemotherapy. Metaphase and interphase FISH analyses were performed on sorted cell fractions, as described by Kroef et al. 1 Probes used in this study were Vysis LSI 7q D7S486 SO/CEP7 SG (for resp. 7q31 and centromere 7), Vysis LSI 5q ERG-1 SO/D5S23 SG (for resp. 5q31 and 5p15.2), D8Z2 (for centromere 8) and DYZ1 (for centromere Y).
Transplantation regimens
Two conditioning regimens for allogeneic stem cell transplantation (SCT) and autologous SCT were recommended. One regimen was cyclophosphamide 60 mg/kg/day on 2 consecutive days and total body irradiation (TBI) 12 Gy in four to six fractions over 2 or 3 days. The alternative regimen was busulphan 4 mg/kg/day on 4 consecutive days in combination with cyclophosphamide 60 mg/kg/day on 2 days. Prophylaxis of graft-versus-host disease (GVHD) following allogeneic SCT consisted of cyclosporine A alone or cyclosporine A in combination with methotrexate. T-cell depletion of the allograft was allowed according to the policy of the centers. The minimal required number for a successful harvest was 1¥10 8 /kg nucleated cells and 2¥10 6 CD34 + cells/kg (autologous peripheral blood SCT).
Definitions
The World Health Organization (WHO) classification was not available at the onset of the study. Therefore the FrenchAmerican-British (FAB)-classification was used throughout the study, but we also classified the patients according to the percentage of marrow blasts, which allows a distinction between refractory anemia with excess blasts (RAEB)-1 and RAEB-2 according to the WHO-classification. Therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) (tMDS/tAML) was defined as MDS or AML supervening after chemotherapy or radiotherapy for an earlier (non)-malignant disease.
Secondary AML (sAML) or transformed MDS was defined as AML after documented MDS lasting 6 months or longer. The Cancer and Leukemia Group B criteria for response to treatment and relapse were used. 
Stratification procedures
Randomization (autologous peripheral blood SCT versus high-dose cytarabine) was stratified for center, response to first induction cycles (complete response versus partial response) and cytogenetic risk groups [ 
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poor prognosis: -5, 5q-, -7, 7q-, +8, complex versus all other single abnormalities versus technical failure versus not done) using a minimization technique. We used this cytogenetic stratification because the IPSS cytogenetic risk classification was published after the start of this study. For the analysis of the results we applied the IPSS cytogenetic classification. The main difference is the inclusion of trisomy 8 in the IPSS intermediate risk group (Online Supplementary Table S1 ).
3
Details of allogeneic stem cell transplantation procedures
Bone marrow was the source of stem cells for 18 patients and peripheral blood stem cells mobilized after administration of granulocyte colony-stimulating factor were used in 29 patients. Forty-five out of 47 patients were treated with a marrow ablative conditioning regimen. This was a TBI-containing regimen in 26 patients and a busulphan-containing regimen in 19 patients (incomplete data for 2 patients). T-cell depletion was used in 18 patients.
Variable
Number of patients (%) 4-yr survival rate (SE%) Hazard ratio P value* (95% CI) 
